Literature DB >> 15487449

The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.

Katie B Weber1, Kenneth R Shroyer, David E Heinz, Samia Nawaz, M Sherif Said, Bryan R Haugen.   

Abstract

In this retrospective histologic study, galectin-3 had a sensitivity of 92% (22/24) for papillary thyroid carcinoma and 44% (4/9) for follicular thyroid carcinoma. Thyroid peroxidase (TPO) had a sensitivity of 50% (12/24) for papillary and 11% (1/11) for follicular carcinoma. The combination of galectin-3 and TPO had a sensitivity of 96% (23/24) for papillary and 44% (4/9) for follicular carcinoma. From a prognostic standpoint, of patients whose papillary carcinomas expressed both markers, all became free of disease. Of those whose papillary carcinomas expressed galectin-3 but not TPO, 57% (4/7) became free of disease, 29% (2/7) had persistent disease, and 14% (1/7) had progressive disease. This study confirms previous observations that galectin-3 alone is highly sensitive for papillary carcinoma but not adequately sensitive for follicular carcinoma. TPO alone is not adequately sensitive for the evaluation of any thyroid lesion. The combination of galectin-3 and TPO is complementary as a diagnostic and prognostic tool for patients with papillary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15487449     DOI: 10.1309/UUQT-E505-PTN5-QJ7M

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  28 in total

1.  Binding of Toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages.

Authors:  Françoise Debierre-Grockiego; Sebastian Niehus; Bernadette Coddeville; Elisabeth Elass; Françoise Poirier; Ralf Weingart; Richard R Schmidt; Joël Mazurier; Yann Guérardel; Ralph T Schwarz
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

Review 2.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Thyroid nodules.

Authors:  Geanina Popoveniuc; Jacqueline Jonklaas
Journal:  Med Clin North Am       Date:  2012-03       Impact factor: 5.456

Review 4.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 5.  Galectins in cancer: carcinogenesis, diagnosis and therapy.

Authors:  Ali Hasan Ebrahim; Zainab Alalawi; Leonardo Mirandola; Rahman Rakhshanda; Scott Dahlbeck; Diane Nguyen; Marjorie Jenkins; Fabio Grizzi; Everardo Cobos; Jose A Figueroa; Maurizio Chiriva-Internati
Journal:  Ann Transl Med       Date:  2014-09

6.  ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

7.  Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

Authors:  Husain A Saleh; Bo Jin; John Barnwell; Opada Alzohaili
Journal:  Diagn Pathol       Date:  2010-01-26       Impact factor: 2.644

8.  Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3.

Authors:  April L Darrow; Ralph V Shohet; J Gregory Maresh
Journal:  Physiol Genomics       Date:  2011-07-26       Impact factor: 3.107

9.  A case of papillary thyroid carcinoma in struma ovarii and review of the literature.

Authors:  W D Salman; Mayuri Singh; Z Twaij
Journal:  Patholog Res Int       Date:  2010-08-02

Review 10.  Controversies in thyroid pathology: the diagnosis of follicular neoplasms.

Authors:  Stefano Serra; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.